EUVIMEDEUVIMED entdecken
Crossref

Abstract TH105: Aldosterone-Induced Platelet Spleen Tyrosine Kinase Overexpression Promotes Arterial Thrombosis in Primary Aldosteronism via Mineralocorticoid Receptor Activation

Yongbo Ma, Mingzhu Wang, Deyu Fu, Liang Hu

Hypertension · 2026-10 · 83 (Suppl_1)

DOI: 10.1161/hyp.83.suppl_1.th105 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hypertension, 2026-10. Verfasst von Yongbo Ma und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Primary aldosteronism (PA) is a common cause of secondary hypertension and significantly increases the risk of arterial thrombotic events including myocardial infarction and stroke, yet the underlying mechanisms remain unclear. This study aimed to investigate the role and regulatory mechanism of aldosterone in platelet activation and arterial thrombosis, and to evaluate the therapeutic potential of mineralocorticoid receptor antagonists (MRAs).

Methods

We enrolled patients with essential hypertension (EH), PA, and PA patients undergoing standard spironolactone therapy. Hyperaldosteronism mouse models were generated by continuous aldosterone infusion using osmotic minipumps. Platelet functions were assessed by aggregation, granule secretion, spreading, and clot retraction. Arterial thrombotic potential was evaluated in vivo using mesenteric and carotid artery thrombosis models, and in vitro by thrombus formation under physiological flow. RNA-seq and ChIP-seq were performed in megakaryocytes to screen for target genes of the mineralocorticoid receptor (MR), and their transcriptional regulation was further validated by Electrophoretic Mobility Shift Assay (EMSA) and luciferase reporter assays. Platelet-specific spleen tyrosine kinase (Syk-/-) mice were used for mechanistic validation. Mouse models of myocardial infarction (MI) were established to define the impacts of hyperaldosteronism and targeted interventions on infarct size and cardiac function.

Results

PA patients and PA mice exhibited marked platelet hyperactivity, with significantly stronger activation induced by collagen than by ADP or thrombin, characterized by enhanced aggregation, spreading, granule release, clot retraction, and arterial thrombus formation. Aldosterone did not directly activate platelets but acted on megakaryocytes, promoting MR nuclear translocation and transcriptional reprogramming. Integrated transcriptomic and ChIP-seq analysis identified Syk as a critical downstream target of MR. PA patients and PA mice exhibited increased Syk expression and pathway activation. Genetic deletion of Syk abolished aldosterone-induced platelet hyper-reactivity and thrombosis. Treatment with spironolactone (in PA patients) and finerenone (in PA mice) both significantly attenuated Syk expression, platelet activation, and arterial thrombus formation. Furthermore, finerenone treatment alleviated myocardial injury in PA mice with MI.

Conclusion

Aldosterone activates MR in megakaryocytes to transcriptionally upregulate Syk, thereby inducing platelet hyperactivation and promoting arterial thrombosis. MRAs constitute a promising therapeutic strategy for the prevention and treatment of thrombotic complications in PA patients.

Zitieren

APA

Ma, Y., Wang, M., Fu, D., & Hu, L. (2026). Abstract TH105: Aldosterone-Induced Platelet Spleen Tyrosine Kinase Overexpression Promotes Arterial Thrombosis in Primary Aldosteronism via Mineralocorticoid Receptor Activation. Hypertension, 83(Suppl_1). https://doi.org/10.1161/hyp.83.suppl_1.th105

Vancouver

Ma Y, Wang M, Fu D, Hu L. Abstract TH105: Aldosterone-Induced Platelet Spleen Tyrosine Kinase Overexpression Promotes Arterial Thrombosis in Primary Aldosteronism via Mineralocorticoid Receptor Activation. Hypertension. 2026;83(Suppl_1). doi:10.1161/hyp.83.suppl_1.th105

BibTeX
@article{Ma2026,
  author = {Ma, Yongbo and Wang, Mingzhu and Fu, Deyu and Hu, Liang},
  title = {Abstract TH105: Aldosterone-Induced Platelet Spleen Tyrosine Kinase Overexpression Promotes Arterial Thrombosis in Primary Aldosteronism via Mineralocorticoid Receptor Activation},
  journal = {Hypertension},
  year = {2026},
  volume = {83},
  number = {Suppl_1},
  doi = {10.1161/hyp.83.suppl_1.th105}
}
Kostenlos starten →